Resources & Insights

Discover common pitfalls and mitigation strategies used when partnering with separate clinical operations and biometrics CROs.

Exec. Director of Strategy Paul Johnson discusses biomarker-driven approaches for complex pulmonary trials.

PharPoint’s Exec. Dir. of Strategy Paul Johnson discusses the use of enrichment strategies in complex pulmonary trials.

PharPoint’s Exec. Dir. of Strategy Paul Johnson discusses the use of adaptive trial design for complex pulmonary trials.

Exec. Dir. Strategy Development Paul Johnson kicks off the first article in a series on pulmonary trial design.

How can we make sure artificial intelligence (AI) is used ethically and responsibly in clinical research? Hear from PharPoint’s VP of Operations.

PharPoint’s Exec. Director of Client Experience explains where customer service can fall short, based on conversations after a recent move.

Explore the basics of quality by design, critical to quality factors, and what risks management means in the context of ICH E6(R3).

This short video takes a behind-the-scenes look at PharPoint’s 6-8 week standard database build process.

A look at a decade of Phase 1-4 studies in Japan and Taiwan, from 2015 to 2025 according to ClinicalTrial.Gov.